Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (BLUE). Such investors are advised to contact Robert S. Willoughby firstname.lastname@example.org or 888-476-6529, ext. 237.
The investigation concerns whether bluebird and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 10, 2015, the Company announced in an Securities and Exchange Commission (SEC) filing the outcome from the National Institutes of Health Recombinant DNA Advisory Committee (“RAC”) review of the protocol from bluebird’s proposed HGB-208 clinical trial of its LentiGlobin product candidate in pediatric subjects with Beta-thalassemia Major. The RAC recommendation was to delay initiation of the study in the United States for one to two years.
On this news, shares of bluebird fell $2.45 per share, to $184.18, or more than 1.55%, on June 10, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. Seewww.pomerantzlaw.com.
Robert S. Willoughby